Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials


The Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Publication date
May 2023
Number of pages
Product type
Research report
Available formats
PDF document
Report edition

The Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.


  • Trends in vaccine and adjuvant partnering deals
  • Partnering agreement structure
  • Partnering contract documents
  • Top deals by value
  • Most active dealmakers
  • Average deal terms for vaccines


This report contains a comprehensive listing of all vaccine partnering deals announced since January 2016, including financial terms where available, including over 900 links to online deal records of actual vaccine partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The report takes readers through the vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering vaccine partnering deals.

The report presents average financial deal terms values for vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 900 online deals records of actual vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

Finally the report concludes by looking into the future of vaccine partnering. With so many innovators looking for the next big thing in the field, the report selects companies to watch who are predicted to become big in the field based on their current dealmaking and financial trends.

Throughout the report various tables, figures and graphs are embedded in order to illustrate the trends and partnering activities of the vaccine field.

By the end of the report prospective dealmakers will have gained a thorough understanding of the partnering landscape of the vaccine market and will be familiar with the values and structures of the deals being signed within it.


Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials is intended to provide the reader with an in-depth understanding and access to vaccine trends and structure of deals entered into by leading companies worldwide.

Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials includes:


  • Trends in vaccine dealmaking in the biopharma industry since 2016
  • Access to headline, upfront, milestone and royalty data
  • Access to over 900 vaccine deal documents
  • The leading vaccine deals by value since 2016
  • Most active vaccine dealmakers since 2016
  • The leading vaccine partnering resources


In Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Therapy target
  • Specific technology type


Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials report provides comprehensive access to available deals and contract documents for over 900 vaccine deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise vaccine rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Vaccine Partnering Terms and Agreements 2016-2023: Deal trends, players and financials provides the reader with the following key benefits:


  • In-depth understanding of vaccine and adjuvant deal trends since 2016
  • Access to headline, upfront, milestone and royalty data
  • Comprehensive access to over 950 actual vaccine deals entered into by the world’s biopharma companies, together with contract documents if available
  • Detailed access to actual vaccine contracts enter into by leading bio pharma companies
  • Identify leading vaccine deals by value since 2016
  • Identify the most active vaccine dealmakers since 2016
  • Insight into the terms included in a vaccine agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in vaccines dealmaking


2.1. Introduction
2.2. Vaccines partnering over the years
2.3. Most active vaccines dealmakers
2.4. Vaccines partnering by deal type
2.5. Vaccines partnering by therapy area
2.6. Deal terms for vaccines partnering
        2.6.1 Vaccines partnering headline values
        2.6.2 Vaccines deal upfront payments
        2.6.3 Vaccines deal milestone payments
        2.6.4 Vaccines royalty rates


Chapter 3 – Leading vaccines deals


3.1. Introduction
3.2. Top vaccines deals by value


Chapter 4 – Most active vaccines dealmakers


4.1. Introduction
4.2. Most active vaccines dealmakers
4.3. Most active vaccines partnering company profiles


Chapter 5 – Vaccines contracts dealmaking directory


5.1. Introduction
5.2. Vaccines contracts dealmaking directory


Chapter 6 – Vaccines dealmaking by technology type




Appendix 1 – Vaccines deals by company A-Z


Appendix 2 – Vaccines deals by stage of development


Phase I
Phase II
Phase III


Appendix 3 – Vaccines deals by deal type


Asset purchase
Bigpharma outlicensing
Collaborative R&D
Equity purchase
Joint venture
Material transfer
Spin out
Technology transfer


Appendix 4 – Vaccines deals by therapy area


Central Nervous System
Orphan disease


Appendix 5 – Deal type definitions

Appendix 6 – Further reading on dealmaking

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Vaccines partnering since 2016
Figure 2: Active vaccines dealmaking activity since 2016
Figure 3: Vaccines partnering by deal type since 2016
Figure 4: Vaccines partnering by disease type since 2016
Figure 5: Vaccines deals with a headline value
Figure 6: Vaccines deals with an upfront value
Figure 7: Vaccines deals with a milestone value
Figure 8: Vaccines deals with a royalty rate value
Figure 9: Top vaccines deals by value since 2016
Figure 10: Most active vaccines dealmakers since 2016

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license


A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

2A, 3D Medicines, 4D Pharma, 7 Hills Pharma, A*STAR’ Institute of Molecular and Cell Biology, ABEC, Abera Bioscience, ABL Bio, Abnova, Abogen Biosciences, Abramson Cancer Center, AbVacc, Academy of Military Medical Sciences (China), Accelovance, Acuitas Therapeutics, AcuraBio, Adaptive Phage Therapeutics, AdaptVac, ADImmune, Adjuvance Technologies, Aduro BioTech, Advaccine Biotechnology, Advanced BioNutrition, Advanced BioScience Laboratories, Advent International, Aegis Life, Aelix Therapeutics, Aerogen, Affinivax, Afrigen Biologics, AGC Biologics, Agenus Bio, AIM ImmunoTech, Akers Biosciences, Akshaya Bio, Akston Biosciences, Albany Molecular Research, Alberta Cell Therapy Manufacturing, Alcami, Aldevron, Algenex, Alpine Immune Sciences, Altimmune, Amaran Biotechnology, American Dental Association, American Gene Technologies, American Type Culture Collection (ATCC), AmerisourceBergen, Amyris, Angany, AnGes MG, Anixa Biosciences, Annias Immunotherapeutics, Annogen, Antigen Express, Apceth, Apollomics, Appili Therapeutics, Applied DNA Sciences, Aptar Pharma, Aptimmune Biologics, Araclon Biotech, Aragen Bioscience, Arcturus Therapeutics, Ardigen, Aridis Pharmaceuticals, Artes Biotechnology, Aruvant Sciences, Asopharma, Astellas Pharma, AstraZeneca, AuraVax Therapeutics, Aurobindo Pharma, Australian Research Council, Avantor, Avanzcare, Avid Bioservices, Avidea Technologies, Baidu, Batavia Biosciences, Battelle, Bavarian Nordic, Baxter International, Bayer, Baylor College, Baylor College of Medicine, Beijing Minhai Biotechnology, Beth Israel Deaconess Medical Center, BGI, Bharat Biotech, BIA Separations, Bill and Melinda Gates Foundation, Binex, Bintai Kinden, BioCina, BioComo, Biodextris, BioElpida, Biofabri, Biofactura, Bio Farma, Biogen, BioIQ, BioIVT, Biolexis, BioLife Solutions, Biological E, biologistex CCM, Biomedical Advanced Research and Development Authority, Biomedical Primate Research Centre, BiondVax, BioNet Holding, BioNTech, BioSun Pharmed, BioTechnique, Biotechnology Industry Research Assistance Council, Biothera Pharmaceuticals, Biovac, BioVaxys, Biovian, Blanver, Bluebird Bio, Blue Water Vaccines, BlueWillow Biologics, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bonnie J. Addario Lung Cancer Foundation, BostonGene, Botanical Solution, Bpifrance, BravoVax, Brickell Biotech, Bristol-Myers Squibb, Broad Institute, BTG, Burnet Institute, Butantan Institute, Button Capital, Calimmune, CanSinoBIO, CARB-X, Cardiff University, Carnegie Mellon University, CaroGen, Catalent, Catholic University Leuven, CCT Research, Celdara Medical, CellCarta, CellVax Therapeutics, Celonic, Cel Sci, Celsion, Centers for Disease Control and Prevention, Centogene, Ceva Sante Animale, Cevec Pharmaceuticals, Changchun BCHT Biotechnology, Charles River Laboratories, Children's Hospital Boston, Chimeron Bio, China National Biotech Group (CNBG), CimCure, Cincinnati Children’s Hospital Medical Center, CIRION BioPharma Research, Citranvi Biosciences, City College of New York, City of Hope, City of Hope Comprehensive Cancer Center, CK Life Sciences, Clarametyx Biosciences, ClearPath, Cleveland Clinic, Clover Biopharmaceuticals, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Codagenix, Codiak BioSciences, Cofactor Genomics, CoImmune, Colombia Ministry of Health and Social Protection, Colorado State University, Columbia University, ConserV Bioscience, Corden Pharma, COVAX, COVAXX, Cristal Therapeutics, Critical Path Institute (C-Path), Croda, Crozet BioPharma, CSIRO, CSL, Curapath, Curative Biotechnology, CureVac, CVC, CyanVac, Cystron Biotech, Cytiva, CYTLIMIC, Cytovance Biologics, Cytovant Sciences, Dalton Pharma Services, Dana-Farber Cancer Institute, Danish Innovation Fund, DCPrime, Debiopharm, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Delpharm, Department of Defence, Department of Defense, Department of Health and Human Services, Diamyd Medical, DIOSynVax, DNA Script, DNAtrix, Dow Chemical, Dr. Reddy's Laboratories, Duke-NUS Graduate Medical School Singapore, Dyadic International, Dynavax Technologies, DynPort Vaccine Company, DZNE German Center for Neurodegenerative Diseases, Eddingpharm, Elanco, Elicio Therapeutics, Eli Lilly, Elixirgen, Emergent BioSolutions, Emergex Vaccines, Emmes, Emory University, Emulate, EmVenio Research, Enara Bio, Endo International, Enesi Pharma, Engility, Ennaid Therapeutics, Entos Pharmaceuticals, Enzychem Lifesciences, EpiThany, Epivax, EpiVax Therapeutics, Epygen Biotech, Ervaxx, Esperovax, eTheRNA immunotherapies, Ethris, Eureka Eurostars, Eurocine Vaccines, Eurofarma, European Commission, European Union, European Union Regional Development Fund, European Vaccine Initiative, Evax, Evaxion Biotech, Everest Medicines, EVQLV, Evvivax, eWorldwide Group, ExcellGene, Excivion, eXmoor Pharma, Exothera, ExpreS2ion Biotechnologies, Eyam Vaccines and Immunotherapeutics, Eyegene, Fareva Holding, Farmacore Biotechnology, Fatro, Federal Ministry of Education and Research (BMBF), Fina Biosolutions, Flaskworks, Flow Pharma, FluGen, Food and Drug Administration (FDA), Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Frame Cancer Therapeutics, Frazier Healthcare Ventures, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Fujifilm Diosynth Biotechnologies, Gamaleya National Center, Gastro-Intestinal Research Foundation, GAVI Alliance, GC Pharma, GE Healthcare, Genentech, Generex Biotechnology, Genetic Immunity, Geneva Foundation, Genevant Sciences, Genexine, Gennova Biopharmaceuticals, Genocea Biosciences, Genomma Lab Internacional, GenScript ProBio, George Mason University, Georgetown University, Georgia Institute of Technology, Georgia State University Research Foundation (GSURF), Georgia Tech Research Corporation, GeoVax, German Cancer Research Center, German Federal Ministry of Education and Research, German Government, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, GlaxoSmithKline Biologicals, Global Health Innovative Technology Fund (GHIT), Global Virus Network, Global WholeHealth Partners, GlycoBac, GOG Foundation, Government of Argentina, Government of Australia, Government of Bahrain, Government of Canada, Government of France, Government of Germany, Government of India, Government of Israel, Government of Japan, Government of Netherlands, Government of Serbia, Government of South Korea, Government of Switzerland, Government of The Philippines, Grand River Aseptic Manufacturing, Greenlight Biosciences, Greenwich LifeSciences, Griffith University, Gritstone Bio, GTP Bioways, Guangzhou Institute of Respiratory Disease, Halix, HaloVax, HanaVax, Hanmi Pharmaceutical, Harro Hofliger, Harvard Medical School, Harvard University, Hawaii Biotech, HDT Bio, Healthcare Royalty Partners, Heat Biologics, Hefei Sageland Biotechnology, Helmholtz Zentrum Munchen, Henry M. Jackson Foundation, Hile Bio-Technology, HilleVax, Hoffmann La Roche, Hookipa Pharma, Horizon Discovery, Horizon Europe, Hoth Therapeutics, Howard Hughes Medical Institute (HHMI), HSS, Hualan Biological Bacterin, Hubro Therapeutics, Hudson Institute of Medical Research, hVIVO, Iaso Therapeutics, iBio, Icahn School of Medicine at Mount Sinai, Ichor Medical Systems, Icon, Iconovo, IDT Biologika, IGNITE Immunotherapy, ILiAD Biotechnologies, ImaginAb, ImmBio, Immorna, Immune Design, Immune System Regulation, Immunicum, ImmunityBio, Immunomic Therapeutics, ImmunoPrecise Antibodies, ImmunoScape, Immunovaccine, Immuron, Imophoron, Imperial College London, Imutex, Indian Council of Medical Research, Infectious Disease Research Institute (IDRI), Infor, InnoCentive, Innovate UK, Innovation Norway, Innovo, Inovio, Inovio Pharmaceuticals, InProTher, Inserm Transfert, Inspirevax, Institute for Bioscience and Biotechnology Research, Institute for Molecular Medicine, Institut Gustave Roussy, Institut Pasteur, INTACT Solutions, Integral Molecular, Integrated BioTherapeutics, International AIDS Vaccine Initiative, International Vaccine Institute (IVI), Intravacc, iNtRON Biotechnology, Inventprise, IO Biotech, IOVaxis Therapeutics, IQVIA, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Israel Investment Center, Italian Government, James Hutton Institute, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Government, Jasper Therapeutics, J Craig Venter Institute, Jenner Institute, Jiangsu Recbio Technology, John D. and Catherine T. MacArthur Foundation, Johnson & Johnson, JSC Pharmadis, Jubilant Hollisterstier, Junshi Biosciences, KaliVir Immunotherapeutics, Kaneka, Kansas State University, Kanyr Pharma, Karolinska Institute, KBI BioPharma, Kemin Industries, Kenya Medical Research Institute, Kermode Biotechnologies, Kindred Bio, King Abdullah University for Science and Technology, King Saud University, Kiromic Biopharma, Kleo Pharmaceuticals, Korea Advanced Institute of Science and Technology, Laboratorios Farmaceuticos Rovi, La Jolla Institute for Allergy & Immunology, LakePharma, Last Chance for Children, Lawrence Livermore National Laboratory, Laxisam, Leiden University, Leidos, Leukocare, LG Life Sciences, LianBio, Liminal BioSciences, LimmaTech Biologics, LineaRx, LinKinVax, LiteVax, Longeveron, Lonza, Lumos Pharma, Lung Cancer Research Foundation, mAbsolve, MabVax Therapeutics, Macquarie University, Maersk-Andersen, Magenta Investments, Maryland Technology Development Corporation, Massachusetts General Hospital, Massachusetts Life Sciences Center, Matinas Biopharma, Matrivax, Mayo Clinic, MBF Therapeutics, McGill University, McKesson, McMaster University, MD Anderson Cancer Center, MDimune, Medac, Medicago, Medical University of Vienna, MediciNova, MediGene, Medigen Vaccine Biologics, Medison Pharma, Medlab Clinical, Medytox, Meissa Vaccines, Memorial Sloan Kettering Cancer Center, Mercer University, Merck and Co, Merck KGaA, Merck Sharpe & Dohme, Metaclipse Therapeutics, Mexican National Technology and Science Council, MGFB, Michael J Fox Foundation, Micron Biomedical, Mid-Atlantic BioTherapeutics, Midatech, Mie University, MigVax, Millipore, MilliporeSigma, Minapharm, MinervaX, Ministry of Health, Ministry of Health (Denmark), Ministry of Health (Israel), Ministry of Health, Labor and Welfare, MLU Services, MMS, Moderna, Molecular Assemblies, Molipharma, MorphoSys, MphRx, MSD, MSD Wellcome Trust Hilleman Laboratories, Mucosis, Mundo Sano, Mustang Bio, Mymetics, MYND Life Sciences, myNEO, Mytide Therapeutics, NanoBio, Nanobiotix, NanoPass Technologies, Nanotherapeutics, Nant Africa, NantBioScience, NantKwest, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Cholera and Enteric Diseases, National Institute of Hygiene and Epidemiology, National Institute of Infectious Diseases, National Institute of Standards and Technology, National Institute of Vaccines and Medical Biologicals, National Institute on Aging, National Institute on Deafness and Other Communication Disorders, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Research Council Canada, National Research Council of Canada, National Science Foundation, National Surgical Adjuvant Breast and Bowel Project, Natural Sciences and  Engineering Research Council of Canada, Nature Technology, Naval Medical Research Center, Navigo Proteins, NEC, NEC OncoImmunity, NeoCura Bio-Medical Technology, NeoMed, Neon Therapeutics, Neovacs, Netherlands Cancer Institute, Neuvogen, New Zealand's Foundation for Research, Science and Technology, Nexelis, Noachis Terra, Nobelpharma, Northern RNA, Nouscom, NovalGen, Novartis, Novasep, Novavax, Novo, Novovet, Noxopharm, NRx Pharmaceuticals, Nuance Pharma, Nuformix, NuGenerex Immuno-Oncology, Nunzia Pharmaceutical, Nuravax, Nykode Therapeutics, Ocugen, Ohio State University, Ology Bioservices, Omniose, OncoDNA, OncoImmunity, Oncology Pharma, OncoQR, Open Orphan, Opiant Pharmaceuticals, Oragenics, Oramed Pharmaceuticals, Oravax Medical, OSE Immunotherapeutics, Osivax, Oswaldo Cruz Foundation (Fiocruz), Ottawa Hospital Research Institute, Owkin, Oxgene, Pacific GeneTech, Pall Corporation, Panacea Biotech, Paragon Bioservices, Partnership for Influenza Vaccine Introduction, PATH (Appropriate Technology in Health), PaxVax, PDC*line Pharma, PDS Biotechnology, Pfizer, Pfizer Japan, Pharco Pharma, Pharm-Olam International, PharmaJet, Pharma Science, PHC, Phibro Animal Health, Phil, PhotonPharma, PhysIQ, Pirbright Institute, PlantForm, PnuVax, Pohang University Of Science And Technology, PolyPeptide Group, Poly Pharmaceuticals, Portage Biotech, POSCO International, PPD, Praha Vaccines, Precision NanoSystems, Precision Virologics, Predictive Oncology, Premas Biotech, Premier Inc, PrescribeWellness, Prestige BioPharma, PRIMA BioMed, ProBioGen, Probiomed, Profectus Biosciences, Prokarium, Prophase Labs, Protein Sciences, Provecs Medical, Provention Bio, Providence Therapeutics, PT Bio Farma, Public Health Agency of Canada, Public Health England, Public Health Vaccines, Quebec Government, Quratis, R-Pharm, Rafarma Pharmaceuticals, Ragon Institute, Rapid Dose Therapeutics, Rapid Micro Biosystems, RareCyte, Recipharm, Redbiotec, Refana, Regen BioPharma, Regeneron Pharmaceuticals, Regenstrief Institute, Regenxbio, ReiThera, Rentschler Biotechnologie, Repligen, Reyon Pharmaceuticals, Robert Wood Johnson Foundation, Rockefeller University, RocketVax, Rokote Laboratories, Rubic One Health, Russian Direct Investment Fund, RVAC Medicines, Sabin Vaccine Institute, Saiba, Saint-Gobain Life Sciences, Samsung Biologics, Sanaria, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, SaponiQx, Sartorius, Satio, SAVSU Technologies, Scancell, Scandinavian Biopharma, Science 37, SciSafe, Scottish Enterprise, Scripps Research Institute, SEEK, Selecta Biosciences, Selexis, Sementis, Senai Cimatec, Seoul National University, Seppic, Seqirus, Seres Therapeutics, Serum Institute of India, Shenzhen BioScien Pharmaceuticals, Shenzhen Kangtai Biological Products, Shenzhen Rhegen Biotechnology, Shionogi, Shionogi Pharma, SIGA Technologies, SillaJen, Sinergium Biotech, Sinopharm Group Beijing HuaHong, Sinotek-Advocates International Industry Development, Sinovac Biotech, SiO2 Medical Products, Sirion Biotech, SK Bioscience, Small Business Innovation Research, SmartPharm Therapeutics, Smiths Medical, Soligenix, Sorrento Therapeutics, Southern Research Institute, Southwest Research Institute, Spark Therapeutics, Spicona, Spotlight Innovation, SpyBiotech, SRI International, St. Jude Children's Research Hospital, Stanford University, State of Victoria, Stelis Biopharma, Stellar Biotechnologies, Stimunity, St Jude Medical, Strategic Vaccines, Sudpack Medica, Sunstone Capital, SUNY Upstate Medical University, Sutro Biopharma, SutroVax, Symbiosis, Symvivo, Synairgen, Syngene International, Synthetic Genomics, Tabuk Pharmaceutical, Taiwan Ministry of Economic Affairs, Takara Bio, Takeda Pharmaceutical, Takis Biotech, Talem Therapeutics, TapImmune, Targovax, Tasly Pharmaceuticals, Technical University of Denmark (DTU), TechnoVax, Terumo Blood and Cell Technologies, Texas A&M University, Texas Biomedical Research Institute, Texas Children’s Hospital, Texas Heart Institute, TFF Pharmaceuticals, TFS International, The International AIDS Vaccine Initiative, The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center, Themis Bioscience, The Native Antigen Company, The Parker Institute For Cancer Immunotherapy, Theragent, Therapure Biopharma, Therapyx, Theravectys, Thermo Fisher Scientific, Thomas Jefferson University, Tianjin CanSino Biotechnology, Tiba Biotech, Tobin Scientific, TONIX Pharmaceuticals, Torigen Pharmaceuticals, Touchlight, Trans-Hit Bio, Transgene, Transgene Tasly Biopharmaceutical, Translate Bio, Transtoxbio, Treos Bio, Trianni, TriLink BioTechnologies, Trinity Pharmaceuticals, Tufts University, TYG Oncology, UbiVac, UK Government, UMN Pharma, United Nations Children Fund, Univercells, University Medical Center Groningen, University of Adelaide, University of Alabama at Birmingham, University of Alberta, University of Amsterdam, University of Antwerp, University of Basel, University of British Columbia, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of Chicago, University of Connecticut, University of Copenhagen, University of Edinburgh, University of Geneva, University of Georgia, University of Greifswald, University of Guelph, University of Hawaii, University of Helsinki, University of Houston, University of Liverpool, University of Maryland, University of Maryland Baltimore, University of Maryland School of Medicine, University of Massachusetts Medical School, University of Miami, University of Miami Miller School of Medicine, University of Michigan, University of Montreal, University of Nebraska, University of New South Wales, University of North Carolina, University of Oxford, University of Pennsylvania, University of Pittsburg, University of Queensland, University of Rostock, University of Saskatchewan, University of Southampton, University of Sydney, University of Tennessee, University of Texas, University of Texas at El Paso, University of Texas Health SCience Center at San Antonio, University of Texas Medical Branch, University of the Witwatersrand, University of Tokyo, University of Tubingen, University of Wisconsin-Madison, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Biologic, US Department of Agriculture, US Government, Utrecht University, Vaccibody, Vaccine Formulation Institute, Vaccines Lab SDN BHD, Vaccitech, Vaccizone, Vactech, Valneva, Valo Therapeutics, Variation Biotechnologies, VaxAlta, Vaxart, Vaxcyte, Vaxeal, Vaxess Technologies, Vaxil BioTherapeutics, Vaximm, Vaxine, VaxNewMo, VaxThera, Vaxxas, Vaxxinity, VBI Vaccines, VectorY Therapeutics, Vedantra Pharmaceuticals, Veeva Systems, Veristat, Verndari, Versatope Therapeutics, Vibalogics, Victor Medical, Vigene Biosciences, Vinbiocare Biotechnology, Vinnova, Viome, Viravaxx, Vir Biotechnology, Virchow Biotech, VistaGen Therapeutics, ViveBio, VLP Therapeutics, Voltron Therapeutics, Vrije Universiteit Brussel, Vyriad, Wacker Chemie, Wageningen University, Walter Reed Army Institute of Research, Washington University in St Louis, Weill Cornell Medical College, Wellcome Trust, Western Oncolytics, Westport Bio, Wipro, Wistar Institute, Wockhardt, Wuhan Rhecogen Biotechnology, WuXi Biologics, Wyss Institute, Xencor, Xenetic Biosciences, XtalPi, Y-Biologics, Y-mAbs Therapeutics, Yale University, Yisheng Biopharma, Yunnan Walvax Biotech, ZandCell, Zenoaq, Zhifei Lvzhu Biopharmaceutical, Ziphius Vaccines, Zolovax, Zuellig Pharma China, Zydus Cadila, ZYUS Life Sciences

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!